

























































A Cyanine-Bridged Somatostatin Hybrid Probe for
Multimodal SSTR2 Imaging in Vitro and in Vivo: Synthesis
and Evaluation
Isabelle Heing-Becker,[a] Carsten Grötzinger,[b] Nicola Beindorff,[c] Sonal Prasad,[c, d]
Sarah Erdmann,[b] Samantha Exner,[b] Rainer Haag,[a] and Kai Licha*[a]
Multimodal imaging probes have attracted the interest of
ongoing research, for example, for the surgical removal of
tumors. Modular synthesis approaches allow the construction of
hybrid probes consisting of a radiotracer, a fluorophore and a
targeting unit. We present the synthesis of a new asymmetric
bifunctional cyanine dye that can be used as a structural and
functional linker for the construction of such hybrid probes.
68Ga-DOTATATE, a well-characterized radiopeptide targeting the
overexpressed somatostatin receptor subtype 2 (SSTR2) in
neuroendocrine tumors, was labeled with our cyanine dye, thus
providing additional information along with the data obtained
from the radiotracer. We tested the SSTR2-targeting and
imaging properties of the resulting probe 68Ga-DOTA-ICC-TATE
in vitro and in a tumor xenograft mouse model. Despite the
close proximity between dye and pharmacophore, we observed
a high binding affinity towards SSTR2 as well as elevated uptake
in SSTR2-overexpressing tumors in the positron emission
tomography (PET) scan and histological examination.
Introduction
Multimodal imaging using PET or SPECT (single photon
emission computed tomography) together with fluorescence
imaging has emerged as a promising tool for the development
of new diagnostics and treatment options.[1] Instead of using
different imaging agents for different imaging modalities in
various experimental setups, only one probe is used for all
imaging procedures. The evident advantages for preclinical and
clinical applications include the complementary data obtained
from both modalities having different sensitivities, resolutions
and penetration depths along with a reduction of time, costs
and resources needed.[2]
A major application of hybrid probes lies in the translation
into image-guided oncologic surgery.[3] The different modalities
help the surgeon to first localize the tumor via the PET or SPECT
scan, followed by the identification of tumor margins through
fluorescence imaging, which enables the resection of affected
areas.[4] Beyond intraoperative imaging, hybrid probes are also
interesting for the evaluation of new drug candidates because
the same label can be used for subsequent in vitro, in vivo and
ex vivo studies. In this way, difficulties in data interpretation
resulting from different labels with different biological behavior
are circumvented.
For these purposes, labels consisting of a fluorophore being
either attached to a chelator for radionuclide complexation[5] or
subjected to 18F-fluorination[6] have been developed and
conjugated to specific targeting molecules such as small
molecules,[7] peptides,[8] antibodies[9] or polymers.[10] When
building up hybrid probes, the question arises of how to
position the three components radiotracer, fluorophore and
targeting unit. This aspect is mainly dictated by the availability
of free conjugatable sites of the components. The vast majority
of hybrid probes either contain an extra linking platform (based,
e.g., on lysine[11] or cyclooctyne[12]) or use the radionuclide
chelator as the linker between fluorophore and targeting unit.[3]
In our study, we present a new design approach for the
construction of multimodal imaging probes and employ the
fluorophore as the linking unit between chelator and targeting
moiety. Among the different classes of fluorescent dyes, cyanine
dyes possess a high structural modifiability that can be used to
introduce various functional groups.[13] We exploited this aspect
to design and synthesize a new asymmetric bifunctional
indocarbocyanine (ICC) dye which can serve as a linker between
two heterofunctional groups.
To exemplify the usage of this new ICC dye, we decided to
focus on the radiopeptide 68Ga-DOTATATE that has attracted
particular interest for the construction of multimodal imaging
probes.[3,14] As somatostatin analogs, the peptides Phe1-Tyr3-
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octreotate (TATE) and the closely related Phe1-Tyr3-octreotide
(TOC) target the somatostatin receptor (SSTR) subtype 2, which
can be overexpressed in neuroendocrine tumors (NETs).[15] Their
radiolabeled forms 68Ga-DOTATATE and 68Ga-DOTATOC are the
workhorses in the diagnosis of NETs and represent well-
characterized, clinically used radiodiagnostics for PET imaging
of SSTR2.[16] In these compounds, the DOTA chelator is
connected via the N-terminal amine of the peptide, leaving
only the remaining functional groups of the peptide for the
attachment of a fluorophore. However, Edwards et al. found
that further functionalization of the Lys-residue in TATE with a
cyanine dye led to a poor in vivo tumor uptake and indicates
that functionalization of certain residues in TATE can signifi-
cantly diminish the peptide functionality towards SSTR2.[17] In
other approaches for multimodal SSTR2-imaging, Ghosh et al.
used a chelator with two binding sites as the linker for a
cyanine dye and the peptide TOC as well as a linking platform
to connect all three components.[18] In this case, the dye was
intentionally positioned far away from the peptide to minimize
interactions.
Our study was conceived to investigate whether SSTR2-
targeted imaging is possible when using our bifunctional
cyanine dye as the linker for the DOTA chelator and the
targeting peptide TATE, with the dye being placed directly next
to the pharmacophore. The resulting Ga-DOTA-ICC-TATE probe
was examined in cell experiments and in an SSTR2-overexpress-
ing tumor mouse model to evaluate its targeting and imaging
properties on the in vitro, in vivo and ex vivo level.
Results and Discussion
Synthesis
Different strategies for the molecular design of somatostatin-
based hybrid probes have been developed (Scheme 1A–C)
using the targeting peptide, the chelator or a dedicated
component as the linker. To the best of our knowledge,
employing the fluorophore as the linker for SSTR2-targeting
hybrid probes has not been done so far. We herein present a
synthetic approach that opens up new possibilities for the
construction of multimodal imaging probes. We used this
strategy to create a dye-linked hybrid probe for multimodal
SSTR2-imaging (Scheme 1D). To this end, we selected the
clinically used radiotracer 68Ga-DOTATATE and inserted a
cyanine dye between the chelator and peptide. This molecular
design was achieved by synthesizing an indocarbocyanine dye
carrying two different conjugatable functional groups at the
aromatic moieties. Whereas the functionalization of the indolic
N-substituents is widely known and applied,[19] our design
approach leaves these N-substituents in principle open to
modifications so that physicochemical properties like solubility
or aggregation behavior can be adjusted.
We synthesized the asymmetric ICC dye 1 from a phthali-
mide functionalized Fischer’s base, N,N-diphenylformamidine
and a carboxylic acid containing indolenine precursor, leading
to a good yield of 35% in terms of asymmetric dye synthesis
(Scheme 1E). Hydrazinolysis according to the Ing-Manske
procedure in Gabriel’s synthesis using hydrazine monohydrate
in methanol yielded the new bifunctional ICC dye 2. For the
upscaling of this step, it was crucial to use a microwave setup
for the heating, short heating times and repeated addition of
hydrazine monohydrate in order to obtain good yields of up to
80%. Performing the hydrazinolysis with the indodicarbocya-
nine (IDCC) analog led to a decrease of the yield, unfortunately,
because longer polymethine chains are more prone towards
decomposition by nucleophilic attacks. The water-soluble
bifunctional ICC dye 2 represents a unique linker platform for
various applications, with a carboxylic acid on the one hand
and an aliphatic amine that allows reactions with electrophiles
under mild conditions on the other hand.
The amine functionality of this dye was used to attach a
tert-butyl-protected, HSTU-activated DOTA chelator to obtain
the DOTA-ICC label 3 in a yield of 55% (Scheme 1E). For PET or
SPECT studies, the DOTA chelator can in general form stable
complexes with 64Cu, 68Ga and 111In.[20] The methylene unit
between the aromatic moiety and the amine of the dye was
essential for the amide coupling. Without this additional meth-
ylene unit, harsh conditions were required being incompatible
with acid-labile protecting groups.
Afterwards, conventional coupling of the N-terminus of
TATE to the carboxyl group of the fluorophore was performed,
followed by the removal of the remaining protective groups. In
comparison to other design approaches, the resulting hybrid
probe becomes relatively compact with the dye in direct
proximity to the pharmacophore.
Spectroscopic properties
The new bifunctional ICC dye 2 has a high absorption
coefficient of 130000 Lmol  1 cm  1 in water with an absorption
maximum at 551 nm and an emission maximum at 570 nm
(Figure S1). For the natGa-DOTA-ICC label, the absorption
coefficient amounts to a good value of 80000 Lmol  1 cm  1 with
an absorption maximum at 552 nm and an emission maximum
at 570 nm. No significant changes in the fluorescence behavior
compared to the free dye 2 were observed.
In vitro studies
Toxicity assays demonstrated that the conjugate DOTA-ICC-
TATE does not inhibit either metabolism or proliferation of
human cells, up to a concentration of 10 μM (Figure S2).
The cellular uptake of the DOTA-ICC-TATE conjugate and
the internalization of SSTR2 were analyzed. Therefore, RIN1038
cells overexpressing an SSTR2-GFP fusion protein were used,
allowing direct detection via GFP fluorescence. After incubation
of the cells with the conjugate (1 μM) for 30 minutes, the strong
fluorescent signal arising from the ICC dye could be clearly
colocalized with the internalized vesicle-associated GFP-fused
SSTR2 (Figure 1A), thus indicating the retention of the receptor-




1308ChemBioChem 2021, 22, 1307–1315 www.chembiochem.org © 2020 The Authors. ChemBioChem published by Wiley-VCH GmbH
Wiley VCH Dienstag, 30.03.2021


























































in vitro. According to the quantitative receptor internalization
assay, DOTA-ICC-TATE stimulates the internalization of the
SSTR2-GFP fusion protein in a concentration-dependent manner
at a sub-nanomolar EC50 value of 0.42 nM (Figure S2). The
binding affinity towards SSTR2 was further supported by a
competitive radioligand binding assay using 125I-labeled Tyr11-
somatostatin-14 as a tracer in BON-SSTR2 cells (Figure 1B),
yielding similar and low IC50 values of 0.77�0.3 nM for DOTA-
ICC-TATE and 0.93�0.3 nM for natGa-DOTA-ICC-TATE. These
values are in the range of published values for DOTATATE and
Ga-DOTATATE,[21] thus suggesting that the close vicinity of the
cyanine dye to the peptide TATE does not substantially
influence the peptide functionality in vitro.
Scheme 1. Different design approaches (A–C) for SSTR2-targeting hybrid probes using either the peptide, the chelator or a platform as the linking structure.
D) In this study, the dye is used as the linker. E) Synthesis of the new asymmetric bifunctional indocarbocyanine dye 2 and DOTA-ICC label 3 as well as the
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In vivo imaging and biodistribution
Radiolabeling of the DOTA-ICC-TATE conjugate with 68Ga was
performed at 95 °C over 500 s. Purification yielded the 68Ga-
DOTA-ICC-TATE probe 4 (Scheme 1E) in high radiochemical
purity (>95%) with a molar activity of 40 GBq/μmol.
In vivo PET imaging was performed 41–48 minutes after
injection of 8.8–14.3 MBq (0.2–0.3 nmol) of the 68Ga-DOTA-ICC-
TATE probe into nude mice bearing an SSTR2-overexpressing
tumor on the right and a wild-type tumor on the left shoulder
(Figures S3–S5). As shown in Figure 2A, the tumor could be well
visualized by the PET/MRI scan. The uptake of the probe in the
SSTR2-overexpressing tumor was higher than in the wild-type
tumor with average standard uptake values of 6.6�1.3%
IAmL  1 in the SSTR2-overexpressing tumor and uptake values
of 4.6�0.3% IAmL  1 in the wild-type tumors. Substantial
uptake of the probe was also seen in the kidneys and the
bladder, but generally low in other organs.
Ex vivo biodistribution data were obtained 1 h after injection
in the same tumor mouse model (Figure 2B). The data is in
good agreement with the PET/MRI scans with uptake values of
6.7�1.4%IAg  1 in the SSTR2-overexpressing tumor, being
higher than in the wild-type tumor (4.1�0.2%IAg  1). In other
organs, a high accumulation was found in the kidneys (~
30%IAg  1) and a moderate uptake in the liver (~5%IAg  1).
Uptake in the wild-type BON tumors may be explained by the
expression of other relevant SSTR subtypes, such as SSTR3 and
SSTR5.[22] It is known from the literature that somatostatin
analogs display the second highest affinity for SSTR5 and a
moderate affinity for SSTR3.[21a] These receptor subtypes are
expressed at a comparatively high level in the wild-type BON
cell line, which most likely contributes to the uptake of our
probe in the BON tumor. According to the PET/MRI and
biodistribution data, the clearance route is predominantly renal
with a high uptake in the kidneys (~30%IAg  1). Attaching a
fluorophore to 68Ga-DOTATATE usually causes higher renal
Figure 1. In vitro assessment of the hybrid probe. A) Cellular uptake studies with RIN1038 insulinoma cells overexpressing GFP-fused SSTR2 at their surface
(green). The cells were incubated in medium alone (left) or medium plus 1 μM DOTA-ICC-TATE (red, right). B) Concentration-dependent displacement of the
radioligand Tyr11-SST14 by DOTA-ICC-TATE and natGa-DOTA-ICC-TATE.
Figure 2. A) Illustrative PET/MRI images of an SSTR2-overexpressing BON-tumor-bearing living mouse, acquired 41 min after tail vein injection of 68Ga-DOTA-
ICC-TATE. Pink arrows indicate the SSTR2-overexpressing BON tumor, white arrows indicate the wild-type BON tumor. The scale bar is representative for all
images. 1) T1 coronal MRI image; 2) PET coronal image; 3) T2 FSE 2D transverse MRI and fusion with PET image. B) Ex vivo biodistribution data in xenograft-
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uptake compared to the dye-free 68Ga-DOTATATE,[21,23] leading
to values of up to 70%IAg  1.[14b,18a] The same applies, usually to
a smaller extent, for the uptake in the liver, which is also
influenced by nonpolar structural moieties as typically given by
fluorophores. In our study, the predominance of the renal
clearance route compared to the hepatobiliary route may be
attributed to the relatively hydrophilic indocarbocyanine dye
with a short polymethine chain length, no additional benzene
moieties and the presence of one sulfonate group. The tumor-
to-background ratios 1 h after injection were moderate for the
muscles and low for blood. Other studies with SSTR2-targeting
hybrid probes observed similar values 3–4 h after
injection,[14b,18a] which could be improved when imaging at later
time points, such as 24 or 48 h after injection with 67Ga.[18c]
Histological examination
When tumor sections of mice sacrificed 1 h p.i. were examined
using a confocal laser microscope, no fluorescence above
background level was detected. In particular, no differences
between sections from SSTR2-overexpressing and wild-type
tumor were found. We assumed that the tracer dose chosen for
the PET/MRI scan was not high enough for fluorescence
imaging on the histological level due to the inferior sensitivity
of this method. We therefore repeated the experiment with the
same tumor mouse model and injected 6 nmol of natGa-DOTA-
ICC-TATE. Mice were sacrificed 5 h p.i., and the tumors excised.
Upon confocal laser scanning microscopy of tumor sections
from these mice (Figure 3A), we detected clear differences in
the signals arising from the ICC dye in the probe between the
SSTR2-overexpressing (mean grey value 32.8�5.4) and the
wild-type BON tumor (mean grey value 12.4�3.3), found to be
statistically significant (P=0.005). The necessity of using a
higher dose for fluorescence microscopy due to its sensitivity is
not unexpected as other studies have also used picomolar
doses for PET or SPECT and nanomolar doses for fluorescence
imaging or microscopy.[7,18b,24] Further studies are required to
determine the optimal dose that can be used both for PET and
for ex vivo examinations afterwards, e.g. for cancer staging or
intraoperative frozen section analysis. However, increasing the
amount of peptide for fluorescence imaging might weaken the
image contrast for PET or SPECT due to a lower specific activity
of the tracer.[18b,25]
Conclusion
We present a new modular design approach for the synthesis of
multimodal imaging probes based on a bifunctional cyanine
dye serving as a structural and functional linking unit. Our study
demonstrates that a cyanine dye can serve as the linker in the
comparatively compact SSTR2-targeting hybrid probe 68Ga-
DOTA-ICC-TATE with direct proximity between dye and pharma-
cophore. Using radionuclide and fluorescence imaging modal-
ities, we performed SSTR2-imaging in vitro, in vivo and ex vivo in
SSTR2-expressing cell and tumor mouse models. Our dye-
bridged hybrid probe showed excellent in vitro SSTR2-affinity
and peptide functionality, whereas the in vivo PET imaging
using 68Ga at an early imaging time point needs further
improvements for higher tumor-to-background ratios. Histolog-
ical ex vivo examination using fluorescence microscopy showed
high specificity of the hybrid probe for the SSTR2-overexpress-
ing tumor in comparison to the wild-type tumor.
While previous reports mainly focused on the use of Cy5- or
Cy7-based dyes for image-guided surgery, we employed a Cy3-
based fluorophore due to chemical considerations during the
establishment of the synthesis. In comparison to Cy7-based
probes, a Cy3-based probe has its own eligibility because
in vitro and histological ex vivo examinations after PET or SPECT
studies can be easily performed using conventional
fluorescence microscopes for detection. Future studies aim to
Figure 3. Histological ex vivo examination of BON wild-type and SSTR2-overexpressing BON tumors from xenograft-bearing nude mice (n=3) injected with
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expand our synthetic approach to a Cy5-based construct with
additional benefits for the field of image-guided surgery.
Experimental Section
General information
Chemicals were purchased from commercial sources (like Sigma-
Aldrich, TCI, AlfaAesar, ABCR and Fluka). Indolenine precursors and
the protected DOTA chelator were synthesized according to
published procedures. 1H, 13C and 71Ga NMR spectra in solution
were measured with the spectrometers ECX 400 (400 MHz) and ECP
500 (500 MHz) from JEOL and Avance 500 (500 MHz) and Avance
700 (700 MHz) from Bruker. Mass spectra were measured on a 6210
ESI-TOF and 6230 ESI-TOF from Agilent. UV/VIS spectra were
recorded using a PerkinElmer LAMBDA 950 UV/Vis/NIR spectrom-
eter and fluorescence spectra recorded using a JASCO FP-6500
spectrometer. NP automated column chromatography was done on
a CombiFlash Rf (Teledyne ISCO) using prepacked silica columns
(30 μm). Purification of compounds using size exclusion chromatog-
raphy was done on a Sephadex column (NAP-25, Sephadex G-25
DNA) with water as eluent.
Synthesis
N-(Hydroxymethyl)-phthalimide: To a solution of phthalimide (10.0 g,
68.0 mmol, 1.0 equiv) in H2O (35 mL) was added a formaldehyde
solution (37% in H2O, 5.1 mL). After heating the suspension to
105 °C for 1 h under heavy stirring, a clear and colorless solution
was obtained. Storing the solution in the freezer overnight led to
the precipitation of a colorless solid, which was filtered off and
washed with ice-cold water. The filter cake was dried in vacuo at
30 °C and afforded the product as a colorless solid (10.9 g,
61.5 mmol, 90%). 1H NMR ([D6]DMSO, 400 MHz): δ=7.93–7.88 (m,
4H;   CH), 6.39 (t, J=7.0 Hz, 1H;   OH), 4.96 (d, J=6.9 Hz, 2H;   CH2);
13C NMR ([D6]DMSO, 101 MHz): δ=167.4, 134.8, 131.6, 123.4, 60.1;
MS (ESI+): m/z C9H7NO3 [M+Na]
+ calculated: 200.0324, found:
200.0318.
1,3,3-Trimethyl-2-methylene-5-(phthal-imidemethyl)-indolenine: Fisch-
er’s base (10.9 mL, 10.7 g, 51.6 mmol, 1.0 equiv) was dissolved in
concentrated H2SO4 (55 mL). To the red-brown solution, N-
(hydroxymethyl)phthalimide (10.9 g, 61.5 mmol, 1 equiv) was added
portion-wise over 45 min. The brown solution was stirred at room
temperature for 75 h and poured onto ice-cooled water (60 mL).
After addition of ammonia solution (12.5% in water, 400 mL) and
filtration, the filter cake was dissolved in CH2Cl2 (350 mL) and
washed with demineralized water (2×300 mL). The aqueous phase
was extracted with dichloromethane (2×400 mL), dried over
Na2SO4, filtered and the solvent removed under reduced pressure.
After automated column chromatography (silica gel, eluent CH2Cl2/
MeOH with 0–5% and 0–0.5% methanol), recrystallization with
CH2Cl2/EtOH (1 :1) and washing with methanol was done and
afforded the product as a yellow to red solid with minor impurities
(8.9 g, ca. 27 mmol, ca. 52%). 1H NMR (CDCl3, 400 MHz): δ=7.81
(dd, J=5.4 Hz, J=3.0 Hz, 2H;   CH), 7.67 (dd, J=5.5 Hz, J=3.1 Hz,
2H;   CH), 7.24 (d, J=1.8 Hz, 1H;   CH), 7.18 (d, J=1.8 Hz, 1H;   CH),
6.44 (d, J=8.0 Hz, 1H;   CH), 4.74 (s, 2H;   CH2), 3.81 (s, 2H;   CH2),
2.98 (s, 3H;   CH3), 1.30 (s, 3H;   CH3);
13C NMR (CDCl3, 126 MHz): δ=
168.3, 163.0, 146.3, 138.1, 134.0, 132.4, 128.9, 126.6, 123.4, 123.0,
104.7, 73.5, 44.2, 41.8, 30.0, 28.9; MS (ESI+): m/z C21H20N2O2 [M+
H]+ calculated: 333.1604, found: 333.1649, [M+Na]+ calculated:
355.1423, found: 355.1468.
Dye 1: 5-Carboxy-1,3,3-trimethyl-2-methylene-1-(4-sulfobutyl)
indolenine (1.12 g, 4.28 mmol, 1.0 equiv) and N,N-diphenylformami-
dine (420 mg, 4.28 mmol, 1.0 equiv) were dissolved in acetic
anhydride (34.3 mL) and heated to 120 °C for 20 min. To the red-
brown solution was then added a suspension of 1,3,3-trimethyl-2-
methylene-5-(phthalimidomethyl)indoline (1.02 g, 4.28 mmol,
1.0 equiv) and sodium acetate (525 mg, 12.8 mmol, 3.0 equiv) in
acetic anhydride (17.1 mL). Afterwards, acetic acid (1.55 mL) was
added dropwise, which led to a color change to pink-violet. The
reaction mixture was stirred at 120 °C for 30 min. The solvent was
removed under reduced pressure and the residue taken up in DMF
for precipitation of the dye by adding diethyl ether (3x). The
precipitate was purified by automated column chromatography
(silica gel, eluent dichloro-methane/methanol with 0–50% meth-
anol) and afforded product 1 as a pink-red solid (1.01 g, 1.48 mmol,
35%). Rf=0.5 (CH2Cl2/MeOH 1 :1);
1H NMR (CD3OD, 500 MHz): δ=
8.57 (t, J=13.5 Hz, 1H;   CH), 8.16–8.12 (m, 2H;   CH), 7.94–7.89 (m,
2H;   CH), 7.89–7.83 (m, 2H;   CH), 7.64 (d, J=1.7 Hz, 1H;   CH), 7.53
(dd, J=8.2 Hz, J=1.7 Hz, 1H;   CH), 7.44 (d, J=8.7 Hz, 1H;   CH), 7.40
(d, J=8.3 Hz, 1H;   CH), 6.59 (d, J=13.6 Hz, 1H;   CH), 6.55 (d, J=
13.3 Hz, 1H;   CH), 4.95 (s, 2H;   CH2), 4.21 (t, J=7.4 Hz, 2H;   CH2),
3.75 (s, 3H;   CH3), 2.95 (t, J=6.8 Hz, 2H;   CH2), 2.08–1.98 (m, 2H;
  CH2), 1.82 (s, 6H;   CH3), 1.79 (s, 6H;   CH3);
13C NMR ([D6]DMSO,
176 MHz): δ=175.5, 173.3, 167.7, 167.0, 149.8, 145.4, 141.9, 141.2,
140.4, 134.6, 131.6, 130.6, 127.8, 123.3, 121.7, 112.1, 110.9, 104.7,
102.7, 50.8, 49.2, 48.3, 43.7, 40.8, 31.8, 27.5, 27.1, 26.0, 22.5; MS (ESI
+): m/z C38H39N3O7S [M+H]
+ calculated: 682.2588, found: 682.2581,
[M+Na]+ calculated: 704.2406, found: 704.2408.
Dye 2: Dye 1 (50.0 mg, 73.3 μmol, 1.0 equiv) was dissolved in
methanol (3.75 mL, purged with Argon) and hydrazine monohy-
drate (10.7 μL, 11.0 mg, 220 μmol, 6.0 equiv) was added in two
portions over 15 min. The reaction mixture was heated to 90 °C in
the microwave for 30 min. The solvent was removed under reduced
pressure. Purification of the residue by column chromatography
(silica gel, eluent CH2Cl2/MeOH with 0–60% methanol) afforded
product 2 as a pink-red solid (32.5 mg, 58.9 μmol, 80%). Rf=0.05
(CH2Cl2/MeOH 1 :1);
1H NMR (CD3OD, 500 MHz): δ=8.57 (t, J=
13.5 Hz, 1H;   CH), 8.11–8.07 (m, 2H;   CH), 7.60 (d, J=1.7 Hz, 1H;
  CH), 7.47 (d, J=7.9 Hz, 1H;   CH), 7.38 (d, J=3.6 Hz, 1H;   CH), 7.36
(d, J=3.1 Hz, 1H;   CH), 6.55 (d, J=10.3 Hz, 1H;   CH), 6.52 (d, J=
10.6 Hz, 1H;   CH), 4.21 (t, J=7.3 Hz, 2H;   CH2), 3.95 (s, 2H;   CH2),
3.73 (s, 3H;   CH3), 2.96 (t, J=6.7 Hz, 2H;   CH2), 2.07–2.01 (m, 2H;
  CH2), 1.82 (s, 6H;   CH3), 1.81 (s, 6H;   CH3);
13C NMR (CD3OD,
176 MHz): δ=176.9, 176.3, 152.2, 144.9, 143.5, 142.6, 141.5, 139.3,
136.7, 131.7, 129.7, 124.4, 123.2, 112.4, 111.4, 104.6, 104.3, 51.6,
50.7, 50.3, 45.8, 45.1, 31.9, 30.8, 28.4, 28.2, 27.1, 23.5; UV/Vis (H2O):
λmax (ɛ)=551 nm (130000 Lmol  1 cm  1); fluorescence (H2O): λex=
530 nm, λem=570 nm; MS (ESI+): m/z C30H37N3O5S [M+H]
+ calcu-
lated: 552.2454, found: 552.2515, [M+Na]+ calculated: 574.2346,
found: 574.2332.
DOTA-ICC label 3: The tert-butyl protected DOTA chelator (68.5 mg,
109 μmol, 1.2 equiv) and HSTU (45.5 mg, 127 μmol, 1.4 equiv) were
dissolved in DMF (750 μL) and DIPEA (23.1 μL, 17.6 mg, 136 μmol,
1.5 equiv) was added. The reaction mixture was stirred for 1 h at
room temperature. Compound 2 (50.0 mg, 90.6 μmol, 1.0 equiv)
was dissolved in demineralized water (1.2 mL) and added with
DIPEA (46.2 μL, 35.1 mg, 272 μmol, 3.0 equiv) to the reaction
mixture. After stirring for 15 h at room temperature, the solvent
was removed under reduced pressure. The residue was purified
twice by automated column chromatography (silica gel, eluent
CH2Cl2/MeOH with 0–100% methanol) and afforded product 3 as a
pink-red solid (59.5 mg, 51.1 μmol, 56%). Rf=0.3 (CH2Cl2/MeOH
1 :1); 1H NMR (CD3OD, 400 MHz): δ=8.55 (t, J=13.4 Hz, 1H;   CH),
8.13–8.09 (m, 2H;   CH), 7.56 (d, J=1.5 Hz, 1H;   CH), 7.44–7.37 (m,
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  CH), 4.50 (b, 2H;   CH2), 4.19 (t, J=6.7 Hz, 2H;   CH2), 3.75 (s, 3H;
  CH3), 3.64–3.37 (m, 4H;   CH2), 3.21–3.00 (b, 4H), 2.95–2.89 (m, 4H;
  CH2), 2.83–2.37 (m, 8H;   CH2), 2.36–2.14 (b, 4H;   CH2), 2.07–1.92
(m, 6H;   CH2), 1.79 (s, 6H;   CH3), 1.78 (s, 6H;   CH3), 1.58–1.55 (m, 2H;
  CH2), 1.50 (s, 9H;   CH3), 1.48 (s, 18H;- CH3);
13C NMR (CD3OD,
176 MHz): δ=177.8, 175.5, 174.5, 174.4, 174.2, 171.8, 152.4, 147.2,
143.1, 142.8, 141.9, 138.7, 132.4, 129.3, 124.6, 123.0, 112.8, 111.8,
105.8, 104.2, 82.8, 57.3, 56.8, 51.6, 51.0, 50.0, 49.9, 45.0, 43.9, 43.4,
32.3, 28.5, 28.1, 27.0, 23.5; MS (ESI+): C60H90N8O13S [M+Na]
+
calculated: 1185.6246, found: 1185.6234, [M+2Na-3 C4H8]
2+ calcu-
lated: 520.2127, found: 520.2144.
natGa-DOTA-ICC label: A mixture of TFA/demineralized water/phenol/
thioanisol/1,2-ethandithiol (82.5 : 5 : 5 : 5 : 2.5, 1.5 mL) was added to
the DOTA-ICC label 3 (61.6 mg, 52.9 μmol, 1.0 equiv) and stirred for
4 h at room temperature. The solvent was removed under reduced
pressure, the residue taken up with water and washed with CH2Cl2.
The aqueous phase was lyophilized. Preparative HPLC was
performed in an isocratic mode on a high-pressure gradient system
(stainless steel), equipped with a Shimadzu LC-8 A pump, Shimadzu
CBM-20 A controller, variable wavelength UV detector from Knauer
and a Rheodyne injector with 10 mL sample loop. The stationary
phase was a prepacked LUNA HILIC diol column (200 Å, 5 μM, 250×
21.2 mm) from Phenomenex with precolumn. The eluent was a
degassed MeCN/water mixture (75% MeCN+50 mM ammonium
formate) and a flow rate of 20 mLmin  1 was applied. Detection was
performed at 480 nm. The appropriate fractions were lyophilized to
afford the deprotected DOTA-ICC label (14.9 mg), which was then
dissolved in water (800 μL). GaCl3 was added and the pH value
adjusted to 4 using NaOH. The reaction mixture was heated at 80 °C
for 30 minutes. The mixture was diluted with water, dialyzed
(regenerated cellulose (Carl Roth), MWCO=500 gmol  1, water, 3 d)
and lyophilized to afford the product as a pink-red solid (14.0 mg,
13.2 μmol, 25% over 2 steps). 1H NMR (D2O/CD3CN 5 :2, 700 MHz):
δ=8.80 (t, J=13.5 Hz, 1H), 8.35 (d, J=1.6 Hz, 1H), 8.35–8.33 (m,
1H), 7.77 (d, J=1.7 Hz, 1H), 7.68 (dd, J=8.1, 1.6 Hz, 1H), 7.65 (dd,
J=11.9, 8.2 Hz, 2H), 6.73 (d, J=13.7 Hz, 1H), 6.66 (d, J=13.2 Hz,
1H), 4.76 (d, J=3.3 Hz, 2H), 4.40 (t, J=7.4 Hz, 2H), 4.27 (dd, J=15.2,
3.8 Hz, 3H), 4.24 (s, 2H), 4.15 (d, J=11.2 Hz, 2H), 4.12 (s, 1H), 4.10 (s,
1H), 4.06 (s, 3H), 4.03 (s, 3H), 3.95 (s, 3H), 3.76 (s, 3H), 3.74–3.72 (m,
3H), 3.59 (ddt, J=14.3, 8.3, 4.4 Hz, 6H), 3.50 (td, J=14.3, 4.4 Hz, 2H),
3.22 (t, J=7.4 Hz, 2H), 2.21 (dq, J=21.9, 7.6 Hz, 4H), 2.06 (s, 6H),
2.04 (s, 6H); 13C NMR (D2O/d3-MeCN 5 :2, 176 MHz): δ=176.6, 174.6,
173.5, 173.2, 171.5, 171.0, 169.1, 151.1, 145.5, 142.1, 141.8, 140.9,
136.6, 131.1, 130.0, 128.1, 123.6, 121.6, 111.9, 110.8, 104.1, 102.5,
63.4, 61.5, 59.7, 57.4, 57.3, 54.7, 54.5, 50.7, 49.8, 49.0, 44.0, 42.8, 42.5,
39.2, 31.7, 27.6, 27.2, 26.0, 22.1; 71Ga NMR (D2O, 153 MHz): δ=-25.0;
UV/Vis (H2O): λmax (ɛ)=552 nm (80000 Lmol  1 cm  1); fluorescence
(H2O): λex=530 nm, λem=570 nm; MS (ESI+): C48H63GaN8O13S [M+
Na]+ calculated: 1082.3305, found: 1082.3322; MS (ESI-):
C48H63GaN8O13S; [M-H]
+ calculated: 1059.3413, found: 1059.3402.
DOTA-ICC-TATE conjugate: The peptide conjugate was synthesized
in a 0.05 mmol scale on a Thr-preloaded Wang Resin. The synthesis
was carried out on a PTI synthesizer (Protein Technologies, USA)
with double couplings of each amino acid (5 equiv. amino acid for
40 min) in DMF. Both cysteines were introduced as MMT protected
building blocks. The DOTA-ICC label 3 (100 μmol, 2.0 equiv) was
coupled manually using HATU (100 μmol, 2.0 equiv) and DIPEA
(200 μmol, 4.0 equiv) in DMF (2 mL) for 4 h. Afterwards, MMT
protecting groups were cleaved by treating the resin 5x with a
mixture of CH2Cl2/TFA/TIS (94 :1 :5; 3 mL) for 2 min. Followed by a
CH2Cl2 and DMF wash, the cyclization using N-chlorosuccinimide
(2 equiv) in DMF for 15 min was carried out. The final cleavage from
the resin was done in TFA/TIS/H2O (95 :2.5 : 2.5) for 3 h. The crude
DOTA-ICC-TATE conjugate was purified by preparative HPLC (RP-
C18, 0–5 min 95 :5, water (0.1% TFA)/MeCN (0.1% TFA); 5–60 min
10 :90, water (0.1%TFA)/MeCN (0.1% TFA)) using a Gilson PLC 2020
personal Purification System (Gilson Inc., Middleton, WI, USA)
including a Nucleodur column (VP250/32 C18 HTec, 5 μm) from
Macherey-Nagel with a flow rate of 30 mLmin  1. The product was
gained in two peaks as a pink powder (9.5 mg, 4.7 μmol, 5%) and
analyzed by UPLC-UV using an Aquity UPLC H-Class with a
quaternary solvent manager, a Waters autosampler and an Aquity
UPLC-BEH RP-C18 column (1.7 μm, 2.1×50 mm) from Waters with a
flow rate of 0.6 mLmin  1 connected to a Waters UV detector and a
QDa detector and the following gradient used with solvents A and
B (A=H2O+0.1%TFA; B=MeCN+0.1%TFA): 0–1.5 min (with 5% B in
A); from 1.5–13 min (5% B to 95% B in A); 13–13.9 min (with 95% B
in A); 13.91–15 min (with 5% B in A). Detection was performed at
220 nm. UV/Vis (H2O): λmax (ɛ)=553 nm (74000 Lmol  1 cm  1);
fluorescence (H2O): λex=530 nm, λem=570 nm; m/z C97H128N18O24S3
[M+2H]2+ calculated: 1013.93, found: 1013.81 and 1013.62, [M+H
+Na]2+ calculated: 1024.93, found: 1024.75 and 1025.01, [M+3H]3+
calculated: 676.29, found: 676.25 and 676.35.
natGa-DOTA-ICC-TATE conjugate: GaCl3 (217 μg, 1.24 nmol, 5.0 equiv)
in 205.6 μL HEPES buffer and 25 μL MeCN was added to DOTA-ICC-
TATE (500 μg, 247 nmol, 1.0 equiv). The pH of the solution was
adjusted to pH 4 using HCl (1 M) and the reaction mixture heated
to 90 °C for 1 h. After cooling down, the purification was done by
using a Sephadex column and water as eluent. The fractions were
lyophilized, dissolved in 1.0 mL water and the concentration was
determined via absorption spectroscopy using an absorption
coefficient of 80000 Lmol  1 cm  1 to be 64 nmol. Analytical RP-HPLC
of the natGa-labeled peptide conjugate in comparison to the Ga-free
peptide conjugate was performed on an Agilent 1200 system
(Agilent, Waldbronn, Germany) equipped with an Eclipse XDB  C18
bonded silica (5 μm, 50×4.6 mm) column (Agilent, Waldbronn,
Germany) with a flow rate of 1 mLmin  1 and the column at 55 °C.
Elution was performed using a linear gradient with solvents A and
B (A=H2O+0.1%TFA; B=MeCN+0.1%TFA) with a gradient of 20–
60% B in A over 20 min. Detection was performed at 543 nm.
Radiolabeling with 68Ga
Radiolabeling experiments were performed on a synthesis module
(Modular Lab PharmTracer) which allows fully automated cassette-
based labelling of Gallium tracers utilizing a Pharmaceutical grade
68Ge/68Ga Generator (GalliaPharm, 1.85 GBq, GMP) both purchased
from Eckert & Ziegler GmbH. Cassettes were GMP-Conform, sterile
and used without pre-conditioning of the cartridges. Gallium-
generator at 1-month post calibration was eluted with aqueous HCl
(0.1 M, 7 mL) and the eluate was purified on an ion-exchange
cartridge followed by elution directly into the reactor pre-heated at
40 °C using 1 mL of 0.1 M HCl in acetone. An aliquot of DOTA-ICC-
TATE, 20 μg (stock solution, 1 μg/μL in water) was mixed with
500 μL HEPES buffer (0.1 M in WFI, pH 7) and added to the reactor
before starting the synthesis. The reaction mixture (pH 3–4) was
then heated for 500 s at 95 °C. After the reaction, the reactor was
cooled with 0.5 mL of saline following the transfer of the contents
of the reactor on a C18 cartridge (SEPPAK, Waters GmbH) for post-
purification. After washing the C18 cartridge with saline, the product
was eluted with 1 mL of ethanol/water (1 :1) and diluted with
1.5 mL saline for animal experiments. RP-HPLC (Knauer) with a
Eurospher II column (C18, 250×4 mm) was used to quantify the
radiochemical purity of 68Ga-DOTA-ICC-TATE. The HPLC was
equipped with an Azura P.6.1 L pump coupled with ultraviolet
(Azura UVD 2.1L) and radiometric (γ-Raytest-Isotopenmessgeräte
GmbH) detectors. The gradient elution system used mobile phase A
(100% acetonitrile) and mobile phase B (deionized H2O containing
0.1% trifluoroacetic acid) and a flow rate of 1.0 mL/min. Starting
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25 min and finally returned to initial gradient conditions over 5
minutes. Radiochemical purity of the tracer was found to be�95%,
radiochemical yield was about 40% and specific activity was
calculated as 40 GBq/μmol of peptide.
In vitro tests
Toxicity tests: BON-SSTR2 cells were seeded in quadruplicates in 96
well plates at a density of 5,000 cells per well and grown overnight.
Cells were treated with the indicated concentrations of DOTA-ICC-
TATE in 100 μL medium per well. Metabolic activity and cell number
were determined after another 96 h. For this, 100 μL medium
containing AlamarBlue™ redox indicator (ThermoFisher) were
added on top of each well, incubated for 3–4 h and the resulting
fluorescence was measured using an EnVision Multilabel Plate
Reader (PerkinElmer). Afterwards, the supernatant was removed;
cells were fixated with 4% v/v formaldehyde for 10 min and stained
with 1 μg/mL DAPI in PBS/0.1% v/v Triton for another 10 min. Four
fields per well were imaged using an IN Cell Analyzer 1000 (GE
Healthcare) with a 4x objective and nuclei were counted by
Investigator software (GE Healthcare). All values were normalized to
the control treated with vehicle and analyzed using GraphPad
Prism 5.04.
Endocytosis assay: Rat insulinoma RIN1038 cells stably expressing a
ratSSTR2-GFP fusion protein almost exclusively show green cell
membrane fluorescence in the resting state while in the presence
of a functional agonist, the receptor-GFP fusion protein is trans-
located to a perinuclear endocytic vesicle compartment. This shift is
readily recognized by inspection of the fluorescent image and can
be detected by software-based quantitation algorithms. After an
incubation time of 30 min with 1 μM DOTA-ICC-TATE in RPMI1640
medium at 37 °C, cells were fixed for 10 min using 4%
formaldehyde in PBS, air-dried and mounted on glass slides with
ImmuMount (ThermoFisher Scientific). Mounted cells were imaged
using a confocal laser-scanning microscope (LSM510, Carl Zeiss)
with a helium–neon laser at 488 and 543 nm, BP505-525 and LP560
emission filters and a 63x NeoFluar oil immersion objective. For
quantitative analysis and determination of the concentration of
half-maximal internalization effect (EC50), eleven concentrations of
DOTA-ICC-TATE (3 pM–300 nM) were used in the same cell model
in quadruplicates in a 96 well plate. After an incubation time of
30 min with 1 μM DOTA-ICC-TATE in RPMI1640 medium at 37 °C,
cells were fixed for 10 min using 4% formaldehyde plus 0.1 μgmL  1
DAPI in PBS before adding 100 μL of PBS per well. For automated
microscopy, microscopic fluorescence images were recorded by an
IN Cell Analyzer 1000 (GE Healthcare) with 20x magnification at 5
frames per well in a 96 well format. Image processing was
performed with In Cell Investigator software (GE Healthcare)
applying the provided granularity algorithm. The output of the
analysis was indicated as vesicle area/cell and was utilized for
calculation of concentration-response curves resulting in the
determination of half-maximal activity (EC50).
In vitro binding affinity assay: 10 nmol Tyr11-somatostatin-14 (Tyr11-
SST14, Bachem, Bubendorf, Switzerland) were iodinated by the
chloramine T method[26] with 1 mCi carrier-free Na125I
(NEZ033 L010MC, PerkinElmer) and purified by HPLC (Analytic HPLC
1200 Series, Agilen). For competitive radioligand binding assays,
40000 BON cells or BON-SSTR2 cells (overexpressing human
SSTR2)[22] were seeded in 96-well plates and grown overnight. The
next day, cells were incubated in binding buffer (50 mM HEPES,
pH 7.4, 5 mM MgCl2, 1 mM CaCl2, 0.5% w/v BSA, complete protease
inhibitors (Roche)) containing 100000 counts per minute (cpm)
[125I]-Tyr11-SST14 and increasing concentrations of unlabeled pep-
tide. After 30 min at 37 °C, cells were washed with ice-cold washing
buffer (50 mM Tris·HCl, pH 7.4, 125 mM NaCl, 0.05% w/v BSA), lysed
with 1 N NaOH, transferred to vials and measured in a gamma
counter (Wallac 1470 Wizard, PerkinElmer). The obtained cpm
values were analyzed with GraphPad Prism 5.04 and IC50 values
were calculated by nonlinear regression (one site-fit logIC50, least
squares fit).
In vivo imaging and biodistribution
Tumor model. Neuroendocrine BON and BON-SSTR2 cells (3x106)
were suspended in a volume of 150 μL 0.9% NaCl and inoculated
subcutaneously on the right and left shoulder of female nude
NMRI-Foxn1nu/Foxn1nu mice (Janvier Labs, Saint-Berthevin, France).
After 2–3 weeks of tumor growth, the tumor size was sufficient for
imaging. Animal care followed institutional guidelines, and all
experiments were approved by local animal research authorities
(approval no. G0192/08).
PET/MRI imaging. Tomographic imaging was performed using the
dedicated small animal 1 Tesla nanoScan PET/MRI (Mediso,
Hungary). Tumor-bearing mice (n=3) were anaesthetized with
isoflurane and were given an injection of 8.8–14.3 MBq 68Ga-DOTA-
ICC-TATE in a volume of 150 μL into the tail vein for PET. PET scans
were performed for 20 min starting 41–48 min after injection of the
probe. The uptake of 68Ga-DOTA-ICC-TATE in the BON and BON-
SSTR2 tumors was determined by manual contouring of a volume-
of-interest (VOI) of the PET image using PMOD 3.5 (PMOD
Technologies Ltd., Switzerland). An average standard uptake value
was computed from the 10 hottest voxels within the 68Ga-DOTA-
ICC-TATE positive lesions. MRI-based attenuation correction of the
PET was conducted with the T1-weighted material map (matrix
144×144×164, with dimensions 0.5×0.5×0.6 mm3, TR:15 ms, TE
2.1 ms and a flip angle of 25°). Further anatomic MRI scans were
acquired using a T2-weighted 2D fast-spin echo sequence (T2-FSE
2D) with the following parameters: transverse sequentially, 224×
224×26, 0.3×0.3×1.0 mm3, TR: 5409 ms, TE: 84 ms and a flip angle
of 180°.
Biodistribution study: Tumor-bearing mice (n=3) were injected with
approximately 5 MBq of 68Ga-DOTA-ICC-TATE in a volume of 150 μL
0.9% NaCl into a lateral tail vein via a catheter. Mice were sacrificed
by cervical dislocation and dissected 1 h after injection. Tumors,
blood, stomach, pancreas, small intestine, colon, liver, spleen,
kidney, heart, lung, muscle and femur samples were weighed and
uptake of radioactivity was measured by a gamma counter (Wallac
1470 Wizard, PerkinElmer).
Histological ex vivo examination: Tumor-bearing mice (n=3) were
injected with approximately 6 nmol of natGa-DOTA-ICC-TATE in a
volume of 150 μL 0.9% NaCl into a lateral tail vein. Mice were
sacrificed and dissected 5 h after injection. Sections of tumors were
fixed for 10 min using 4% formaldehyde in PBS, air-dried and
mounted on glass slides with ImmuMount (ThermoFisher Scientific).
Tissues were imaged using a confocal laser-scanning microscope
(LSM510, Carl Zeiss) with a helium-neon laser at 543 nm, LP560
emission filter and a 63x NeoFluar oil immersion objective.
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